Related Experiment Videos
[JSH guidelines for the management of hepatitis C virus infection (version 3)]
Insights
New guidelines offer advanced direct-acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) management. These recommendations include IFN-free options and a new flowchart for patients with cirrhosis.
Area of Science:
- Hepatology
- Virology
- Clinical Practice Guidelines
Context:
- Recent advancements in direct-acting antivirals (DAAs) have transformed chronic hepatitis C virus (HCV) management.
- The Japan Society of Hepatology (JSH) has updated its clinical practice guidelines to reflect these therapeutic advancements.
- The introduction of interferon-free DAAs has enabled treatment for patients intolerant or ineligible for interferon-based therapies.
Purpose:
- To summarize the revised Japan Society of Hepatology (JSH) clinical practice guidelines for HCV management.
- To introduce the latest treatment recommendations, including novel antiviral therapies.
- To highlight the inclusion of a new treatment flowchart for cirrhotic HCV patients.
Summary:
- The revised JSH guidelines incorporate the latest direct-acting antivirals (DAAs), including interferon-free regimens like daclatasvir (DCV) and asunaprevir (ASV).
- A significant update includes a new treatment flow-chart specifically designed for managing antiviral therapy in patients with liver cirrhosis.
- These revisions aim to optimize HCV treatment strategies, particularly for patients with prior treatment failures or contraindications.
Impact:
- The updated guidelines provide clinicians with evidence-based recommendations for more effective HCV treatment.
- The availability of interferon-free DAAs expands treatment accessibility for a broader patient population, including those with cirrhosis.
- These advancements contribute to improved patient outcomes and the potential for HCV eradication.
Abstract:
Recently, the management of chronic hepatitis C virus (HCV) has been greatly advanced with introduction of direct acting antivirals (DAAs) in clinical setting. The Japan Society of Hepatology (JSH) first released the clinical practice guideline for the management of HCV infection in 2012, and revised in 2013 along with the introduction of a second-generation DAA, simeprevir (SMV). In September 2014, the first IFN-free DAAs, daclatasvir (DCV) and asunaprevir (ASV), were launched and the antiviral therapy for IFN intolerant/ineligible patients became to be possible. Thence the society has now revised the clinical practice guidelines at this time, and added a new treatment flow-chart for the antiviral therapy in patients with cirrhosis. In this article I summarized the revised guidelines and would like to introduce the treatment recommendations.